1XUAN B, CHIOU G C Y. Efficacy of oxymetazoline eye drops in noninfectious conjunctivitis, the most common cause of acute red eyes [ J ]. J Ocul Pharmaeol Ther, 1997,13 (4) : 363 -367.
3Cohen S, Lobel E, Trevgoda A, et al. A novel in situ-forming ophthalmic drug delivery systems from alginates undergoing gelation in the eye [J] .J Controlled Release, 1997,44(2-3) :201.
4Gurny R, Boye T, lbrahim H. Ocular therapy with nanoparticulate systems for controlled drug delivery [J ]. J Controlled Release, 1985,2(3 ): 353.
5Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system [ J ]. J Controlled Release ,2001,73(2) :205.
6Lin HR, Sung KC. Carbopol/pluronic phase change solutions for ophthalmic drug delivery [J ]. J Controlled Release ,2000,69(3 ) :379.
7Yun MO,Choi HG,Jung JH,et al. Development of a thermo-reversible insulin liquid suppository with bioavailability enhancement [J]. Int J Pharm, 1999,189(2) : 137.
8Desai SD,Blanchard J. Evaluation of Pluronic F127 sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model [J ]. J Pharm Sci, 1998,87(10) : 1190.
9Shin SC, Cho CW, Oh IJ. Effect of non-ionic surfactants as permeation enhancers towards piroxicam from the poloxamer gel through rat skins [J]. Int J Pharm ,2001,222(2) : 199.
10Wei G, Xu H, Ding PT, et al. Thermosetting gels with modulated gelation temperature for ophthalmic use: rheological and gamma scintigraphic studies [ J ]. J Controlled Release, 2002,83 ( 1 ) : 65.
